Navigation Links
Debiopharm and Pharmaleads Sign License Agreement for Debio 0827 or PL37 in Treatment of Chronic Pain Conditions
Date:2/9/2009

LAUSANNE, Switzerland and PARIS, February 9 /PRNewswire/ -- Debiopharm Group (Debiopharm), a global biopharmaceutical development specialist that focuses on serious medical conditions and particularly oncology, and Pharmaleads SAS, a science driven drug discovery and early development company, today announced the signature of an exclusive license agreement for the development, registration and commercialisation of a small molecule called Debio 0827 or PL37, about to enter phase I clinical trials. Debio 0827 is the first in a new class of painkillers that could be used in the treatment of chronic pain conditions, primarily in neuropathic pain. Under the terms of the agreement, Debiopharm will make an up-front payment to Pharmaleads, as well as further payments as Pharmaleads reaches predefined development milestones.

"With this agreement we add the new therapeutic area of chronic pain management to the Debiopharm product portfolio. There is currently an unmet medical need for the treatment of chronic pain, which can often not be treated successfully and can seriously affect patients' quality of life. For this reason, we have decided to develop this new therapeutic approach," said Rolland-Yves Mauvernay, President and Founder of Debiopharm Group.

"This exclusive licence agreement is very exciting and promising: it will speed up the development of a totally new class of painkillers, hence confirming the validity of our science and chemistry, as well as our capabilities as a drug discovery and early development company," added Thierry Bourbie, Chairman and CEO of Pharmaleads.

Following authorisation from the French Medicine Agency (AFSSAPS), Debio 0827 is about to enter a single ascending dose Phase I, randomised, double-blind, placebo controlled single oral dose escalation study in France, to investigate its safety, tolerability and pharmacokinetics in healthy volunteers.

About N
'/>"/>

SOURCE Pharmaleads
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Debiopharm and Aurigene Sign Licensing Agreement for the Development and Commercialisation of Debio 0617, a Novel Inhibitor of an Undisclosed Oncology Pathway
2. Japanese Cancer Association and Debiopharm Honour Japanese Research
3. Debiopharm Signs License Agreement for Marketing of Salvacyl(R)/Moapar(R) 3-Month in Treatment of Sexual Deviations
4. Debiopharm and EPFL Establish an Oncology Chair
5. Japanese Cancer Association and Debiopharm Honour Professors Minoru Toyota and Keiichi Nakayama With the 2007 JCA-Mauvernay Award
6. Debiopharm Receives cGMP Certification for Quality Control of its Drug Products
7. The Debiopharm Life Sciences Award Goes to Dr Nusser for his Outstanding Research in Neuroscience
8. Novavax and Vivalis Sign a Research License Agreement to Use the EB66(R) Cell Line for the Production of Virus Like Particle Based Vaccines
9. Cephalon Exercises Option to License Worldwide Rights to ImmuPharma Product, Lupuzor
10. Artemis Health Licenses Prenatal Cell-Free DNA Analysis Technology from Stanford University
11. S*BIO and Tragara Announce an Exclusive Worldwide License Agreement for Novel Multi-kinase Inhibitor SB1317
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)NEW YORK, Dec. 2 Reportlinker.com announces that a new market research report is available in its catalogue: ,, Drug Discovery Technologies - A Global Update of Market Trends & Opportunities ,,
(Date:12/2/2009)TUSTIN, Calif., Dec. 2 Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM ) today reported completion of patient enrollment in a dose confirmation and dosimetry trial of Cotara® in patients with rel
(Date:12/2/2009)LELYSTAD, The Netherlands, December 2 Pepscan Holding NV,the Netherlands based biotechnology company focusing on protein mimicking,technology for the generation of immune therapeutics today announced
(Date:12/2/2009)SINGAPORE, Dec. 2 S*BIO Pte Ltd today announced data presentations on its novel oral JAK2 inhibitor, SB1518, at The American Society of Hematology 51st Annual Meeting and Exposition in New Orleans. ,
Breaking Biology Technology:Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 2Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 3Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 4Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 5Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 6Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 7Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 8Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 9Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 2Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 3Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 4Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 5Dutch Biotech Company Pepscan Appoints New CEO 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 5
...ies, Inc. today,announced that it has entered into...speed chemistry technologies and capabilities to Z...based biopharmaceutical company which,develops obe...ipose tissue., Under the agreement, Anthill will ...d purification capabilities to assist Zafgen in th...
...inical Picture, Improves,Patient-Physician Communi...a A patients who,use Helixate(R) FS, Antihemophili...ers are now tracking treatment progress in real ti...-art wireless Internet-based,data management syste...llows for a comprehensive view of a patient,s prog...
...ternational Corporation (Nasdaq: PRXL ), a leadin...reveal that U.S. marketing,applications for new mo...,While NME approvals reached a many-year low of 16...) launches declined 19 percent to 25, during 2007,... 2007, up from 21 filed,in 2006, according to PARE...
Other Biology Technology:CSL Behring's Innovative HeliTrax(SM) System Helps Physicians Manage Hemophilia A Patients 2CSL Behring's Innovative HeliTrax(SM) System Helps Physicians Manage Hemophilia A Patients 3CSL Behring's Innovative HeliTrax(SM) System Helps Physicians Manage Hemophilia A Patients 4PAREXEL Data Indicate U.S. Marketing Applications for New Molecular Entities Bounce Back 2PAREXEL Data Indicate U.S. Marketing Applications for New Molecular Entities Bounce Back 3PAREXEL Data Indicate U.S. Marketing Applications for New Molecular Entities Bounce Back 4
(Date:12/3/2009)Have you ever felt overly upset by a social snubbing? Your genetics, not your friends, may be at fault. , Scientists have long known that opium-like painkillers, called opioids, relieve not only phys
(Date:12/3/2009)The UK leads the world when it comes to investment in energy efficient technologies research, but Engineering and Physical Sciences Research Council (EPSRC) Chief Executive Dave Delpy believes that mo
(Date:12/2/2009)PHILADELPHIA Children exposed to secondhand cigarette smoke have an increased risk of developing lung cancer in adulthood, even if they never smoked. , Results of this study are published in Cance
Breaking Biology News(10 mins):Research is vital to a cleaner, greener, low carbon future 2Secondhand smoke exposure in childhood increases lung cancer risk later in life 2Cornflakes White Bread Could Boost Heart Risk 48653 1Cornflakes White Bread Could Boost Heart Risk 48653 2Cornflakes White Bread Could Boost Heart Risk 48653 3Pennsylvania Patient Safety Authority Hires Patient Safety Liaison 28PSL 29 to Help Healthcare Facilities Implement Guidance 48651 1Pennsylvania Patient Safety Authority Hires Patient Safety Liaison 28PSL 29 to Help Healthcare Facilities Implement Guidance 48651 2Pennsylvania Patient Safety Authority Hires Patient Safety Liaison 28PSL 29 to Help Healthcare Facilities Implement Guidance 48651 3Study shows promise for new cancer stopping therapy 48649 1Study shows promise for new cancer stopping therapy 48649 2
...mans is often associated with decline and a loss o...alled senescence -- is proving to be one of ironic...tory (CSHL) today reported that a particular class...of events in living mice that can limit fibrosis, ... The surprising finding follows on the heels of e...
... . , Bremerhaven, August 19th 2008. German rese...ener Institute for Polar and Marine Research in th...ssage for the first time. Polarstern left the port...and on a southern course and is located right in t...Siberian Sea where geoscientific measurements at t...
...awaii, the Wildlife Conservation Society, Smithso...Fisheries Service and Projecto Meros do Brazil dis...s more than six feet in length and can weigh nearl...be found roaming the tropical reefs of the Eastern...ong the corals and sea grass to evade marine biolo...
Other Biology News:Senescence in liver cells is found by CSHL scientists to help limit acute tissue damage 2Senescence in liver cells is found by CSHL scientists to help limit acute tissue damage 3Senescence in liver cells is found by CSHL scientists to help limit acute tissue damage 4RV Polarstern on its way to East Siberian Sea 2RV Polarstern on its way to East Siberian Sea 3Genetics reveals big fish that almost got away 2
...bulizers are available in two product models - the... two models is that the 6000AT+ includes a membran... aerosol for improved detection limits and reduced...on limits for a range of elements by 10-40 times. ...
... >95%NEN Radiolabeled Ligands\n\nReceptor-related ...ailability of new radiolabeled ligands selected to...s a wide range of products and services for recept... state-of-the-art radioligands. If you do not find...
AMV RT HC 600 U from Invitrogen
...ding) was developed using a protein engineering ap... DNA binding pocket of wild-type DNase I. These ch...n for DNA. The result is a versatile enzyme that h...intain at least 50% of peak activity in solutions ...
Biology Products: